Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43909642" target="_blank" >RIV/00216208:11120/15:43909642 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/75010330:_____/15:00010790

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.thromres.2015.04.014" target="_blank" >http://dx.doi.org/10.1016/j.thromres.2015.04.014</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.thromres.2015.04.014" target="_blank" >10.1016/j.thromres.2015.04.014</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry

Popis výsledku v původním jazyce

Objective: The present study aimed to compare characteristics related to selection of a P2Y12 antagonist, investigate initiation of therapy with new-generation drugs, and identify predictors of high on-treatment platelet reactivity (HTPR) in patients with acute coronary syndrome treated with stent percutaneous coronary intervention (PCI). Methods and results: Data from 589 patients in the LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry; ClinicalTrials.gov Identifier: NCT02264912)registry was analyzed. P2Y12 receptor antagonist efficacy was measured by VASP phosphorylation 24+-4hours after a loading dose of clopidogrel (600mg, N=407), prasugrel (60mg, N=106), or ticagrelor (180mg, N=76) and expressed by platelet reactivity index(PRI). HTPR was defined as PRI GREATER-THAN OR EQUAL TO50%. Patients treated with prasugrel were significantly younger and had significantly higher hemoglobin levels than those who received clopidogrel or ticagrelor, while chronic kidney

Název v anglickém jazyce

Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry

Popis výsledku anglicky

Objective: The present study aimed to compare characteristics related to selection of a P2Y12 antagonist, investigate initiation of therapy with new-generation drugs, and identify predictors of high on-treatment platelet reactivity (HTPR) in patients with acute coronary syndrome treated with stent percutaneous coronary intervention (PCI). Methods and results: Data from 589 patients in the LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry; ClinicalTrials.gov Identifier: NCT02264912)registry was analyzed. P2Y12 receptor antagonist efficacy was measured by VASP phosphorylation 24+-4hours after a loading dose of clopidogrel (600mg, N=407), prasugrel (60mg, N=106), or ticagrelor (180mg, N=76) and expressed by platelet reactivity index(PRI). HTPR was defined as PRI GREATER-THAN OR EQUAL TO50%. Patients treated with prasugrel were significantly younger and had significantly higher hemoglobin levels than those who received clopidogrel or ticagrelor, while chronic kidney

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Thrombosis Research

ISSN

0049-3848

e-ISSN

—

Svazek periodika

135

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

1093-1099

Kód UT WoS článku

000354497300011

EID výsledku v databázi Scopus

—